- subcutaneous
CJC-1295
CJC-1295 (with and without DAC)
CJC-1295 at a glance
Nomination withdrawnHow studies gave it
Injected into the fat under the skin
Evidence on this page
2 peer-reviewed papers, published 2006
FDA compounding lists
It was nominated for compounding use and the nomination was withdrawn.
Mixing it
CJC-1295 reconstitution calculatorWhat it is
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It has been studied in the context of growth hormone secretion and is available in two forms: with Drug Affinity Complex (DAC) for extended duration, and without DAC (also called Modified GRF 1-29) for shorter activity. It is discussed in communities focused on growth hormone optimization, body composition, and recovery.
Published research
CJC-1295 has been studied in human clinical trials evaluating its effects on growth hormone and IGF-1 levels. Published pharmacokinetic studies have characterized its half-life in both DAC and non-DAC forms. Research has examined its potential in the context of growth hormone deficiency and body composition. The DAC form demonstrated sustained GH elevation over several days in published studies.
Community discussion often focuses on combining CJC-1295 (no DAC) with growth hormone-releasing peptides such as ipamorelin.
What the terms on this page mean8 termsHide
- analog
- A molecule built to copy a natural one with a deliberate change, usually to make it last longer or bind more tightly.
- GH
- Growth hormone, released by the pituitary gland, involved in growth and tissue repair.
- GHRH
- Growth hormone-releasing hormone, the signal that tells the pituitary to release GH.
- clinical trial
- A study that tests something in people under a written plan, with results recorded.
- IGF-1
- Insulin-like growth factor 1, made largely in the liver in response to GH, and the marker most GH studies measure.
- pharmacokinetics
- How fast the body absorbs a substance, where it goes, and how it clears it out.
- half-life
- The time it takes for a drug's concentration in the blood to fall by half. It does not, by itself, determine a dosing schedule.
- peptide
- A short chain of amino acids, the building blocks of proteins.
Compounding status
Nomination withdrawn- FDA lists it as
- CJC-1295
- What that means
- These substances are not eligible for the policy that applies to substances in category 1. FDA would consider taking action against a compounder for compounding drug products with this bulk drug substance under its general enforcement policies.
Source: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA. Content current as of 2026-04-22; read 2026-09-05. This describes what a compounding pharmacy may supply. It is not advice about your own use.
Also given subcutaneous
- CJC-1295 DACCJC-1295 with Drug Affinity Complex (DAC:GRF)Nomination withdrawn
- DihexaN-hexanoic-Tyr-Ile-(6)-aminohexanoic amide (PNB-0408)Nomination withdrawn
- DSIPDelta Sleep-Inducing Peptide (Emideltide)Nomination withdrawn
- EpithalonEpithalon (Epitalon / AEDG Peptide)Nomination withdrawn
- FGLFGL (FG Loop Peptide, NCAM-Derived FGFR1 Agonist)Not on either FDA list
- Follistatin 344Follistatin Isoform FST344Not on either FDA list
Where this came from2 referencesHide
Each one was resolved at PubMed and confirmed to be the work this page cites. Author, title, journal and year come from the PubMed record, not from the page text.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, et al.. The Journal of clinical endocrinology and metabolism (2006). PMID 16352683.
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Frohman LA. The Journal of clinical endocrinology and metabolism (2006). PMID 17018654.
About this page
Reviewed 2026-08-11. This page reports what published studies and FDA documents say. It carries no dose, cycle length or stack, and it does not tell you whether a substance is appropriate for you. Side-effect reports circulating on forums are self-reported rather than measured, so they are not republished here.
See the editorial policy for how corrections are handled.